Back

Decoding the Structural and Functional Impact of the Leukaemia-Associated A338V Mutation in GPR183

Andersson, L.; Wesolowski, P. A.; Jahrstorfer, L.; De Rosa, A.; Heger, T.; Neuman, V.; Sieradzan, A. K.; Wales, D. J.; Kozielewicz, P.

2026-04-01 pharmacology and toxicology
10.64898/2026.03.30.715362 bioRxiv
Show abstract

G protein-coupled receptors rely on dynamic conformational changes to coordinate G protein activation and recruitment of regulatory transducers such as G protein-coupled receptor kinases and {beta}-arrestins. The chemotactic receptor GPR183 has been implicated in a context-dependent role in hematological malignancies. Here, we investigated the impact of A338V mutation located within the C-terminal tail of GPR183. This mutation is associated with acute myeloid leukaemia. Using bioluminescence resonance energy transfer-based assays in HEK293A cells, we assessed receptor-proximal signaling events. The A338V variant displayed preserved agonist potency and comparable agonist-induced Gi activation relative to wild type, although constitutive activity towards Gi was modestly reduced. In contrast, recruitment of GRK2 and {beta}-arrestin2 was consistently impaired across multiple assay configurations. These differences were not attributable to altered receptor abundance, as the C-tail untagged mutant exhibited increased plasma membrane expression despite reduced regulatory transducer engagement. While intramolecular conformational biosensor measurements revealed subtle differences in global receptor conformation between WT and A338V, extensive molecular dynamics simulations supported the altered conformational sampling of the C-terminal tail in the A338V variant. Together, these data support a model in which the A338V substitution selectively alters C-terminal structural dynamics, impairing GRK2 and {beta}-arrestin2 recruitment while preserving G protein activation.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Scientific Reports
3102 papers in training set
Top 5%
10.4%
2
Nature Communications
4913 papers in training set
Top 21%
8.7%
3
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 9%
7.4%
4
Journal of Biological Chemistry
641 papers in training set
Top 0.1%
7.0%
5
eLife
5422 papers in training set
Top 16%
5.0%
6
Science Signaling
55 papers in training set
Top 0.1%
5.0%
7
Molecular Pharmacology
15 papers in training set
Top 0.1%
4.1%
8
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.2%
2.8%
50% of probability mass above
9
PLOS ONE
4510 papers in training set
Top 47%
2.1%
10
Molecular Biology of the Cell
272 papers in training set
Top 1%
1.9%
11
Human Genetics and Genomics Advances
70 papers in training set
Top 0.3%
1.7%
12
EMBO reports
136 papers in training set
Top 2%
1.7%
13
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.3%
1.7%
14
Blood Advances
54 papers in training set
Top 0.7%
1.7%
15
PLOS Genetics
756 papers in training set
Top 10%
1.4%
16
Journal of Molecular Biology
217 papers in training set
Top 2%
1.3%
17
JCI Insight
241 papers in training set
Top 5%
1.3%
18
Science Advances
1098 papers in training set
Top 22%
1.3%
19
Communications Biology
886 papers in training set
Top 16%
1.0%
20
Disease Models & Mechanisms
119 papers in training set
Top 2%
1.0%
21
Science Translational Medicine
111 papers in training set
Top 5%
0.9%
22
FEBS Letters
42 papers in training set
Top 0.2%
0.9%
23
Nucleic Acids Research
1128 papers in training set
Top 15%
0.9%
24
Cancers
200 papers in training set
Top 4%
0.8%
25
Computational and Structural Biotechnology Journal
216 papers in training set
Top 8%
0.8%
26
British Journal of Pharmacology
34 papers in training set
Top 0.4%
0.8%
27
Cell Communication and Signaling
35 papers in training set
Top 1%
0.8%
28
iScience
1063 papers in training set
Top 30%
0.8%
29
PLOS Computational Biology
1633 papers in training set
Top 27%
0.7%
30
Blood Cancer Journal
11 papers in training set
Top 0.3%
0.7%